NEWM&A

GSK (GSK) Acquires Nuvalent for $10.6 Billion to Boost Cancer Portfolio

Published on 6/9/2026

#GSK#M&A#Nuvalent#oncology
GSK (GSK) Acquires Nuvalent for $10.6 Billion to Boost Cancer Portfolio

AI Summary

GSK (GSK) announced a $10.6 billion acquisition of U.S. biotech company Nuvalent, marking its largest purchase in eight years. This move aligns with GSK's strategy to strengthen its cancer portfolio that had been previously reduced. The acquisition could impact GSK's market position in the oncology sector significantly. Analysts will watch for changes in GSK’s stock performance following this transaction.

Source: Read original article (opens in new tab)

Related News

Evoke (EVC) Surges After $326 Million Takeover Agreement
M&A

Evoke (EVC) Surges After $326 Million Takeover Agreement

Jun 9

Bain Capital Bids for oOh!media Amid Rival Offers
M&A

Bain Capital Bids for oOh!media Amid Rival Offers

Jun 9

Vietnam Airlines urged to accelerate U.S. deals amid trade probes
M&A

Vietnam Airlines urged to accelerate U.S. deals amid trade probes

Jun 9

oOh!Media (OML) shares rise on Bain Capital's indicative offer
M&A

oOh!Media (OML) shares rise on Bain Capital's indicative offer

Jun 9